MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica). Ketamir-2, a non-opioid, offers tremendous promise for patients seeking better solutions for neuropathic...Read more
Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment...Read more
RADNOR, Pa. / Oct 17, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating...Read more
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the...Read more
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q4 2024 and topline data in Q1 2025 Data presented at the 22nd International Colloquium on Lung and Airway Fibrosis LA JOLLA, CA, Oct. 16, 2024...Read more
GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading...Read more
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...Read more
Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024. Pre-clinical evaluation of obefazimod combined with etrasimod improved body weight protection and Disease Activity Index with a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone. PARIS, France,...Read more
ReSonance is Manufactured by a Proprietary Process, Developed In-House, at Clinical Scale, with Relevant In-Vitro Functional Activity Immediate-Use, Thaw-and-Inject Formulation Durably Engrafted in Multiple Preclinical Hearing Loss Models ReSonance is Currently Being Evaluated in a Functional Model of Hearing Loss CARLSBAD, Calif. / Sep 18, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a...Read more
Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. NEW YORK, Sept. 17, 2024 /PRNewswire/...Read more
A key aspect of Parkinson’s disease (PD) pathophysiology is decreased systemic regulatory T cell (Treg) function with associated neuroinflammation in the nigrostriatal pathway of the brain, including the presence of reactive astrocytes and microglia that have an initiating and progressing role in PD; Subcutaneous injection of COYA 302, an anti-inflammatory, Treg-enhancing combination biologic (comprising low dose interleukin-2 and CTLA-4...Read more
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the...Read more
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer Strong safety profile for FRA-H with no loss of bodyweight as compared with control in animal models Success of tADC proof-of-concept study paves way for creating multiple potential therapeutic candidates for...Read more
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT WORTH, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products...Read more
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and affecting 5 to 10% of the global population MDNA209 restores immune balance by selectively blocking IL-2Rβγc, a receptor highly expressed by effector CD8 T cells which are known to promote tissue damage in autoimmune diseases In an...Read more
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteria The data confirm that Evaxion’s AI-Immunology™ platform is delivery modality agnostic COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...Read more
TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine New data show improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high doses Tonix’s synthetic horsepox vaccine platform has been selected by NIH’s Project NextGen for clinical testing CHATHAM, N.J., Sept. 09, 2024 (GLOBE...Read more
TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a spinal cord compression model, our team demonstrated that ExoPTEN has a strong ability to target and...Read more
Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously announced sham-implant adjusted preclinical weight loss of 20%, which is comparable to the weight loss produced from the semaglutide (active ingredient in Ozempic®/Wegovy®) injection control arm in the same study Clinical development of...Read more
Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A...Read more
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of...Read more
Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their...Read more
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation,...Read more
Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain Thresholds MIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is proud to announce a major breakthrough in the treatment of neuropathic pain. A recent pre-clinical study in rats demonstrated that its novel oral ketamine analog,...Read more
IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment POTOMAC, Md. / Aug 22, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase separation,...Read more
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time REHOVOT, Israel & EDEN PRAIRIE, Minn., Aug. 19, 2024 /PRNewswire/ -- In a significant step in the...Read more
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive data from preclinical studies that support the potential for NGC-Iri to have improved efficacy and a better side effect profile compared with the commonly...Read more
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments. MIAMI, FL / ACCESSWIRE / August 12, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA Pharmaceuticals, a leading pre-clinical-stage pharmaceutical company unveiled new preclinical data providing further insights into the mechanism of action of its innovative drug candidate, Ketamir-2's principal...Read more
TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results...Read more
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical...Read more
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of...Read more
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders Plans advancing to initiate a clinical trial in individuals with FXS NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...Read more
Confirmation of oral bioavailability and significant brain exposure in rodent models supports expedited development of EB-003, with Investigational New Drug (IND) filing and first patient dosed expected in 2025 CAMBRIDGE, Mass. / Jul 25, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders,...Read more
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology...Read more
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. The additional data announced today...Read more
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15, 2024 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical development company, today announced promising new findings from recent preclinical studies of its novel oral pharmaceutical marijuana analog, MIRA-55, which is being...Read more
BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announces promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G. Duda of...Read more
In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24 CARLSBAD, Calif., July 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in...Read more
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12,...Read more
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (α-synuclein), specifically the A53T mutation, that demonstrate the compounds'...Read more
BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice Non-human primate models of BVP implantation showed islet survival and continued insulin production DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform...Read more
New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potential for safer mental health treatments MIAMI, June 24, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company focused on the treatment of neurologic...Read more
Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO, June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of...Read more
PASADENA, Calif. / Jun 24, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE...Read more
Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...Read more
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central...Read more
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...Read more
DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide Data Presented at the ADA 84th Scientific Sessions CAMBRIDGE, Mass., June 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced...Read more
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination...Read more
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in validated preclinical models TRV045 did not show a statistically significant effect in preliminary preclinical model of epileptogenesis, but results...Read more
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD,...Read more
The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ketamine Unlike ketamine, which requires intravenous or intranasal administration, Ketamir-2's oral formulation promises ease of use and better patient compliance and is not a controlled substance under DEA rules MIAMI, June 10, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the...Read more
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage...Read more
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting,...Read more
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the...Read more
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22, 2024...Read more
Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and neuropathic pain, including cancer pain MIAMI, May 20, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced...Read more
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual Meeting Management webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands &...Read more
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer. The vaccine was shown to be...Read more
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical models Data presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine’s hallmark toxicity...Read more
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor associated antigen, which is overexpressed by immunologically “cold”...Read more
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer...Read more
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T...Read more
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung...Read more
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains previously reported observations in behavioral studies on locomotion, memory and cognition Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - InMed...Read more
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validation of Oncoprex® Delivery System With Another Tumor Suppressor Gene AUSTIN, Texas, April 2, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...Read more
Ketamir-2 is a potential treatment for certain major mental health disorders impacting millions of people in the U.S. MIAMI, April 2, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today shares updates on the ongoing pre-clinical studies of its investigational...Read more
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a...Read more
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company...Read more
NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active pharmaceutical ingredient in NPM-139, with the added potential benefit of once-yearly dosing NPM-115 and NPM-139 are miniature, subdermal implants in development for chronic weight management designed to guarantee...Read more
Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced that René Bernards, PhD, professor of molecular...Read more
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that...Read more
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats...Read more
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine...Read more
WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor...Read more
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatment Monash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP;...Read more
Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) Data to be presented at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024) LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq:...Read more
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the...Read more
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration Administration of anti-CD47 antibody after six months demonstrated the principle of graft ablation and a potential safety strategy SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana...Read more
BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024. The poster presentation includes the...Read more
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009 (formerly GFH009), its potent, highly selective...Read more
BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration. The...Read more
Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism Scholar Rock’s novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading portfolio of innovative, highly selective anti-myostatin treatments under development CAMBRIDGE, Mass. / Feb 06, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on...Read more
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant...Read more
Data served as foundation for current vaccine candidate for planned Phase 2 research Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern Vaccination reduced SARS-CoV-2 shedding following infectious challenge in both the upper and lower airway of non-human primates SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc....Read more
New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL...Read more
Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD, depression & anxiety SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences, Inc. (Magdalena), the joint...Read more
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a...Read more
Preclinical data demonstrated PALI-2108 to be safe and well tolerated PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study, expected to commence in 2024 Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or...Read more
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE